Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 6/20 | 0.48 |
| ▸ | ESR1 | P03372 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3402025 | 0.85 | MAPT (0.44) | KCNA5ESR1MAPTLMNACYP1A2 | |
| SCHEMBL9909376 | 0.84 | KCNA5 (0.64) | KCNA5MAPTPLA2G1BATG4BKMT2A | |
| SCHEMBL5522123 | 0.84 | KCNA5 (0.64) | KCNA5MAPTPLA2G1BATG4BKMT2A | |
| SCHEMBL14567176 | 0.82 | ESR1 (0.48) | ESR1MAPTOPRM1ESR2RAB9A | |
| SCHEMBL13140497 | 0.82 | ESR1 (0.48) | ESR1MAPTOPRM1ESR2RAB9A | |
| SCHEMBL2881396 | 0.82 | ESR1 (0.48) | ESR1MAPTOPRM1ESR2RAB9A | |
| SCHEMBL2498065 | 0.81 | KCNA5 (0.47) | KCNA5MAPTLMNADRD1ADRA1A | |
| SCHEMBL27830813 | 0.81 | KCNA5 (0.47) | KCNA5MAPTLMNADRD1ADRA1A | |
| SCHEMBL2504421 | 0.81 | KCNA5 (0.47) | KCNA5MAPTLMNADRD1ADRA1A | |
| SCHEMBL27565555 | 0.81 | ESR1 (0.46) | KCNA5ESR1MAPTLMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582674-B1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | CYMABAY THERAPEUTICS INC (US) | 2014-10-01 | — | — | EP | disclosed |
| EP-2582674-B1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | CYMABAY THERAPEUTICS INC (US) | 2014-10-01 | — | — | EP | disclosed |
| CN-103980235-A | GPR120 receptor agonists and uses thereof | CYMABAY THERAPEUTICS INC | 2014-08-13 | — | — | CN | disclosed |
| CN-102307860-B | GPR120 receptor agonists and uses thereof | METABOLEX INC | 2014-07-02 | — | — | CN | disclosed |
| US-20140121246-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-8598374-B2 | GPR120 receptor agonists and uses thereof | METABOLEX, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-8476308-B2 | GPR120 receptor agonists and uses thereof | METABOLEX, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476308-B2 | GPR120 receptor agonists and uses thereof | METABOLEX, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476308-B2 | GPR120 receptor agonists and uses thereof | METABOLEX, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20130131351-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20110313003-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2011-12-22 | — | — | US | disclosed |
| US-20110313003-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2011-12-22 | — | — | US | disclosed |
| US-20110313003-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2011-12-22 | — | — | US | disclosed |
| WO-2011159297-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2011-12-22 | — | — | WO | disclosed |
| EP-2367793-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | Metabolex Inc. (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20100190831-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190831-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190831-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2010-07-29 | — | — | US | disclosed |
| WO-2010080537-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010080537-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110313003-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | KCNA5 1964/4885ESR1 831/4885MAPT 4135/4885 |
| US-20100190831-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | KCNA5 1964/4885ESR1 831/4885MAPT 4135/4885 |
| US-20140121246-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | KCNA5 1964/4885ESR1 831/4885MAPT 4135/4885 |
| US-20130131351-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | KCNA5 1964/4885ESR1 831/4885MAPT 4135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.